Trevi Therapeutics Statistics
Want to see TRVI full AI Analyst Report?
Trevi Therapeutics (TRVI) Stock Statistics & Valuation Metrics
Total Valuation
Trevi Therapeutics has a market cap or net worth of $2.13B. The enterprise value is $1.99B.
- Market Cap
- $2.13B
- Enterprise Value
- $1.99B
Share Statistics
Trevi Therapeutics has 142,559,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 142,559,400
- Owned by Insiders
- 1.31%
- Owned by Institutions
- 38.14%
Financial Efficiency
Trevi Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -26.77%.
- Return on Equity (ROE)
- -0.23
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -26.77%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.26M
- Employee Count
- 34
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Trevi Therapeutics is -38.20. Trevi Therapeutics’s PEG ratio is 4.14.
- PE Ratio
- -38.20
- PS Ratio
- 0.00
- PB Ratio
- 7.82
- Price to FCF
- -34.22
- Price to Operating Cash Flow
- -38.52
- PEG Ratio
- 4.14
Income Statement
In the last 12 months, Trevi Therapeutics had revenue of 0 and earned -42.76M in profits. Earnings per share was -0.29.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -49.33M
- Pretax Income
- -42.82M
- Net Income
- -42.76M
- EBITDA
- -42.68M
- Earnings Per Share (EPS)
- -0.29
Cash Flow
In the last 12 months, operating cash flow was -61.44M and capital expenditures -251,000, giving a free cash flow of -61.69M billion.
- Operating Cash Flow
- -61.44M
- Free Cash Flow
- -61.69M
- Free Cash Flow per Share
- -0.39
Dividends & Yields
Trevi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.92%
- Earnings Yield
- -2.57%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- 22.44%
- 50-Day Moving Average
- 14.28
- 200-Day Moving Average
- 14.50
- Relative Strength Index (RSI)
- 58.71
- Average Volume (3m)
- 1.96M
Important Dates
Trevi Therapeutics upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Trevi Therapeutics as a current ratio of 19.66, with Debt / Equity ratio of 0.41%
- Current Ratio
- 19.66
- Quick Ratio
- 19.66
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Trevi Therapeutics has paid -64.00K in taxes.
- Income Tax
- -64.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Trevi Therapeutics EV to EBITDA ratio is -34.33, with an EV/FCF ratio of -33.77.
- EV to Sales
- 0.00
- EV to EBITDA
- -34.33
- EV to Free Cash Flow
- -33.77
- EV to Operating Cash Flow
- -33.91
Balance Sheet
Trevi Therapeutics has $299.41M in cash and marketable securities with $527.00K in debt, giving a net cash position of $298.88M billion.
- Cash & Marketable Securities
- $299.41M
- Total Debt
- $527.00K
- Net Cash
- $298.88M
- Net Cash Per Share
- $2.10
- Tangible Book Value Per Share
- $1.90
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Trevi Therapeutics is $27.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $27.38
- Price Target Upside
- 84.78% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -6.57%
Scores
- Smart Score
- 9
- AI Score
- 60
